Latest news with #StrykerCorporation
Yahoo
10-07-2025
- Business
- Yahoo
What to Expect From Stryker's Next Quarterly Earnings Report
Portage, Michigan-based Stryker Corporation (SYK) operates as a medical technology company that develops, manufactures, and markets specialty surgical and medical products. Valued at $148.7 billion by market cap, the company's products include implants, surgical, neurologic, ear, nose and throat and interventional pain equipment, endoscopic, surgical navigation, digital imaging systems, as well as patient handling and emergency medical equipment. The Medtech giant is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect SYK to report a profit of $3.06 per share on a diluted basis, up 8.9% from $2.81 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. This Underdog AI Stock Just Got a New Street-High Price Target Texas Just Passed Quantum Computing Legislation. How Should You Play IONQ Stock Here? 'The Most Patriotic Thing You Can Do Is Not Pay the IRS' Says Grant Cardone as OBBBA Signed into Law — Here's How Much You'll Save Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect SYK to report EPS of $13.35, up 9.5% from $12.19 in fiscal 2024. Its EPS is expected to rise 11% year over year to $14.82 in fiscal 2026. SYK stock has outperformed the S&P 500 Index's ($SPX) 12.3% gains over the past 52 weeks, with shares up 16.8% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 6.5% dip over the same time frame. SYK thrives on growing procedural volumes and strong capital product demand. On May 1, SYK reported its Q1 results, and its shares closed up more than 1% in the following trading session. Its adjusted EPS of $2.84 exceeded Wall Street expectations of $2.73. The company's revenue was $5.9 billion, exceeding Wall Street forecasts of $5.7 billion. SYK expects full-year adjusted EPS in the range of $13.20 to $13.45. Analysts' consensus opinion on SYK stock is bullish, with a 'Strong Buy' rating overall. Out of 28 analysts covering the stock, 19 advise a 'Strong Buy' rating, two suggest a 'Moderate Buy,' and seven give a 'Hold.' SYK's average analyst price target is $431.77, indicating a potential upside of 10.1% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
05-07-2025
- Business
- Yahoo
Stryker's Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy
Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy. On June 25, Stryker Corporation (NYSE:SYK) announced that its Incompass Total Ankle System, intended for patients with severe rheumatoid, post-traumatic, or degenerative arthritis-related ankle joint damage, received FDA 510(k) clearance. The Incompass system integrates Adaptis Boney Ingrowth Technology and revised instrumentation to facilitate long-term fixation, surgical flexibility, and optimized workflow. According to the company, data from 100,000 clinical cases and over 85,000 CT scans were used in guiding the system's development. Additionally, in support of the company's strategic direction, Stryker Corporation (NYSE:SYK) shareholders recently approved revisions to key incentive plans, such as the 2008 Employee Stock Purchase Plan and the 2011 Long-Term Incentive Plan. Founded in 1981, Stryker Corporation (NYSE:SYK) is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopaedics, MedSurg, and Neurotechnology and Spine. While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Inicia sesión para acceder a tu portafolio
Yahoo
29-05-2025
- Business
- Yahoo
Jim Cramer on Stryker Corporation (SYK): 'I Don't Like It Enough'
We recently published a list of . In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other stocks that Jim Cramer discusses. When a caller asked about Stryker Corporation (NYSE:SYK), Cramer replied: 'I like Stryker, but you know, I don't like it enough. I don't like it as much as if it was Intuitive Surgical. That's the one that I thought we should buy. ISRG.' A medical team wearing surgical masks and gloves carrying out a hip or knee joint replacement surgery with the help of surgical navigation systems. Stryker (NYSE:SYK) is a medical technology company that supplies products like joint implants, spinal systems, surgical tools, patient safety equipment, neurosurgical devices, and other healthcare technologies. Toward the end of March, talking about the company, Cramer stated: 'Stryker is a good company and I think that a medical device company in this environment will do well. Now, there's some people that are gonna say, listen, they're going to be tariffs on that company. I'm not sure whether they'll really matter. I think Stryker works in an environment where we're putting 25% tariffs on all foreign cars. As I've been saying to you, Germany, Japan and Korea have to pay. I've been saying it and saying and saying it and it happened tonight. And people say, why didn't we know? I don't know what else I could do.' Overall, SYK ranks 10th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of SYK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SYK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
27-05-2025
- Business
- Yahoo
Jim Cramer on Stryker Corporation (SYK): 'I Don't Like It Enough'
We recently published a list of . In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other stocks that Jim Cramer discusses. When a caller asked about Stryker Corporation (NYSE:SYK), Cramer replied: 'I like Stryker, but you know, I don't like it enough. I don't like it as much as if it was Intuitive Surgical. That's the one that I thought we should buy. ISRG.' A medical team wearing surgical masks and gloves carrying out a hip or knee joint replacement surgery with the help of surgical navigation systems. Stryker (NYSE:SYK) is a medical technology company that supplies products like joint implants, spinal systems, surgical tools, patient safety equipment, neurosurgical devices, and other healthcare technologies. Toward the end of March, talking about the company, Cramer stated: 'Stryker is a good company and I think that a medical device company in this environment will do well. Now, there's some people that are gonna say, listen, they're going to be tariffs on that company. I'm not sure whether they'll really matter. I think Stryker works in an environment where we're putting 25% tariffs on all foreign cars. As I've been saying to you, Germany, Japan and Korea have to pay. I've been saying it and saying and saying it and it happened tonight. And people say, why didn't we know? I don't know what else I could do.' Overall, SYK ranks 10th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of SYK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SYK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
12-05-2025
- Business
- Yahoo
Joint Replacement Devices Market Analysis and Global Forecast to 2030: Ambulatory Care Centers & Trauma Units Set for Significant Growth Ahead
The global joint replacement devices market is projected to grow from USD 23.42 billion in 2024 to USD 31.09 billion by 2030, exhibiting a 4.8% CAGR. Key drivers include technological advancements like 3D printing, smart implants, and increased accessibility to innovative solutions. The knee replacement devices segment led the market in 2023, driven by the rise in obesity and advancements in robotic-assisted procedures. The total replacement surgery segment also held a significant market share, supported by the increasing number of procedures. Asia Pacific is expected to witness the highest growth due to enhanced healthcare infrastructure. Major players include Zimmer Biomet, Stryker Corporation, and Johnson & Johnson MedTech. Joint Replacement Devices Market Dublin, May 12, 2025 (GLOBE NEWSWIRE) -- The "Joint Replacement Devices Market by Product (Knee, Hip, Shoulder, Ankle, Elbow, Wrist, Bone Grafts), Surgery (Total, Partial, Revision), Type(Cemented, Cementless, Hybrid), Procedure Type, End User (Hospitals, ASC, Trauma, Clinic) - Global Forecast to 2030" has been added to offering. The global joint replacement devices market is projected to grow from USD 23.42 billion in 2024 to USD 31.09 billion by 2030, achieving a CAGR of 4.8% from 2024 to 2030. Technological advancements, such as 3D printing in manufacturing, the advent of smart implants, and enhanced access to innovative implants, are key drivers of market growth. The rising incidence of sports injuries and accidents leading to joint damage further fuels demand for joint replacement devices. Knee Replacement Devices Lead Product Segmentation in 2023 Product segmentation in the market includes knee, hip, shoulder, elbow, ankle, wrist replacement devices, and bone graft substitutes. Knee replacement devices commanded the largest market share in 2023, bolstered by the launch of smart knee replacements, increasing obesity rates, and heightened awareness initiatives. The adoption of robotic platforms in knee replacement procedures significantly enhances patient outcomes, as evidenced by Stryker Corporation's Mako Total Knee Replacement, which offers reduced discomfort and recovery times compared to traditional surgery. Total Replacement Surgery Type Dominates in 2023 Market segmentation by surgery type includes total, partial, and revision replacements. The total replacement segment dominated in 2023, driven by the growing number of knee and hip surgeries and the introduction of durable, corrosion-resistant implants. Advances in robotic surgery, alongside innovative implants that reduce pain and revision rates, support this segment's growth. Significant CAGR for Ambulatory Care Centers and Trauma Units End-user segmentation encompasses hospitals & surgical centers, ambulatory care centers & trauma units, and orthopedic clinics. Ambulatory care centers and trauma units are expected to experience significant growth, driven by a 304% increase in knee replacements performed in outpatient centers from 2018-2022, as per Definitive Healthcare. The accessibility and cost-effectiveness of these centers are pivotal growth factors, alongside growing preference for minimally invasive techniques. Rapid Growth Anticipated in Asia Pacific North America held the largest market share in 2023, but the Asia Pacific region is expected to grow at the highest CAGR. This growth is driven by investments in emerging economies, enhanced healthcare infrastructure, and robust efforts by market leaders to expand in this region. The International Osteoporosis Foundation anticipates that over 50% of osteoporotic hip fractures will occur in the Asia Pacific by 2050. Competitive Landscape The leading players in the joint replacement devices market include Zimmer Biomet Holdings, Inc. (US), Stryker Corporation (US), Johnson & Johnson MedTech (US), Smith+Nephew (UK), B. Braun (Germany), Arthrex, Inc. (US), Enovis (US), Globus Medical, Inc. (US), Acumed LLC (US), Orthofix Medical Inc. (US), MicroPort Scientific Corporation (China), CONMED Corporation (US), Medacta International (Switzerland), Paragon 28, Inc. (US), and Meril Life Sciences Pvt. Ltd. (India). Key Attributes: Report Attribute Details No. of Pages 376 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $23.42 Billion Forecasted Market Value (USD) by 2030 $31.09 Billion Compound Annual Growth Rate 4.8% Regions Covered Global Market Dynamics Drivers Rising Prevalence of Orthopedic Diseases and Disorders Increasing Demand for Minimally Invasive Surgery Rising Adoption of Sensor-based Implants Rising Number of Sports Injuries Increasing Research Funding Restraints Risks and Complications Associated with Orthopedic Surgical Procedures Reduced Reimbursement Rates for Orthopedic Surgeries High Cost of Orthopedic Surgery Opportunities Advancements in Robotic Surgery and 3D Printing Growth Opportunities in Emerging Markets Challenges Dearth of Skilled Orthopedic Surgeons Case Study Analysis Case Study 1: Digital Platform Designed to Improve Patient Care Pathways Case Study 2: Partial Knee Arthroplasty Performed with Rosa Partial Knee System Case Study 3: Accurate Data Generation with Shapegrabber 3D Company Profiles Key Players Zimmer Biomet Stryker Johnson & Johnson Medtech Smith+Nephew B. Braun Globus Medical Arthrex, Inc. Enovis Acumed LLC Orthofix Medical Inc. Microport Scientific Corporation Conmed Corporation Medacta International Paragon 28, Inc. Meril Life Sciences Pvt. Ltd. Gpc Medical Ltd. Maxx Orthopedics, Inc. Auxein Noraker Nextstep Arthropedix Exactech, Inc. Other Players Fh Ortho Symbios Orthopedie SA Madison Ortho Green Surgicals Pvt. Ltd. Siora Surgical Pvt. Ltd. Orthopediatrics Corp. Restor3D Double Medical Technology Inc. Treace Medical Concepts, Inc. Ak Medical For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Joint Replacement Devices Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
